All go for Progen

JUNE 2010

EMBATTLED drug developer Progen Pharmaceuticals (PGL) has been granted a European patent for the preparation and use of its cancer therapeutic Muparfostat (PI-88).

Progen CEO Sue MacLeman says the patent grant will give the company greater coverage in a major pharmaceutical market.

Progen has also announced it plans to sublicence the technology to Taiwanese company Medigen Biotech Corp.

Amid board restructures and uncertainty for the biotech’s future, PGL shares have fallen by around 40 per cent in the last 12 months.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Employee resilience is key to business resilience
Partner Content
Employee mental health and wellbeing is top of mind for Australian businesses, and or...
Aon
Advertisement

Related Stories

Commonwealth raises COVID-19 Disaster Payment to JobKeeper levels

Commonwealth raises COVID-19 Disaster Payment to JobKeeper levels

The Federal Government's COVID-19 Disaster Payment will see e...

Dexus names Dap & Co for Naldham House fitout

Dexus names Dap & Co for Naldham House fitout

Dexus Property Group (ASX: DXS) hopes to restore Brisbane's&n...

Why governments will have to consider the costs of long COVID when easing pandemic restrictions

Why governments will have to consider the costs of long COVID when easing pandemic restrictions

With governments worldwide under pressure to ease pandemic restrict...

Construction starts on $250m CHEP service centre in Brisbane

Construction starts on $250m CHEP service centre in Brisbane

Joint venture (JV) construction partners Goodman (ASX: GMG) and B...